Abstract
The age distribution and incidence of loss of heterozygosity (LOH) of 1p and 19q was analyzed in 85 oligodendroglial tumors WHO II and III. The peak of tumor manifestation was in the age group of 35 to 55 years. There was no association between age at diagnosis and LOH incidence. We conclude that the prognostic effect of age on survival is not mediated by LOH 1p/19q.
This is a preview of subscription content, log in via an institution to check access.
References
Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W, Macdonald D, Stitt L, Cairncross JG (1999) Pre-treatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Rad Oncol Biol Phys 45:923–929
Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Áfra D, Cornu P, Bolla M, Vecht C, Karim ABMF (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084
Shafqat S, Hedley-Whyte ET, Henson JW (1999) Age-dependent rate of anaplastic transformation in low-grade astrocytoma. Neurology 52:867–869
Kunwar S, Mohapatra G, Bollen A, Lamborn KR, Prados M, Feuerstein BG (2001) Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 61:7683–7688
Batchelor TT, Betensky RA, Esposito JM, Pham LDD, Dorfman MV, Piscatelli N, Jhung S, Rhee D, Louis DN (2004) Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 10:228–233
Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479
Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126
Hartmann C, Mueller W, Lass U, Kamel-Reid S, von Deimling A (2005) Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 64:10–14
Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, von Deimling A (1997) Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56: 1098–1104
Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489
Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schüler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lütolf UM, Kleihues P, Ohgaki H (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49–56
Ross FM, Ibrahim AH, Vilain-Holmes A, Winfield MO, Chiecchio L, Protheroe RKM, Strike P, Gunasekera JL, Jones A, Harrison CJ, Morgan GJ, Cross NCP (2005) Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia 19:1634–1642
Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379–385
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hergersberg, M., Mariani, L., Vassella, E. et al. Age at diagnosis and loss of heterozygosity on chromosome 1p and 19q in oligodendroglial tumors. J Neurooncol 80, 215–217 (2006). https://doi.org/10.1007/s11060-006-9177-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-006-9177-2